AGLE News and Press, Aeglea BioTherapeutics Inc. From 05/07/19

Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from February 2019 Public Offering Extends Cash Runway Through Q1 of 2021 Pivotal Phase 3 Tr...

The following slide deck was published by Aeglea BioTherapeutics, Inc. in conjunction with this Read more ...

Aeglea BioTherapeutics (NASDAQ: AGLE ) has presented new positive Phase 1/2 data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) at the 2019 SIMD meeting. More news on: Aeglea BioTherapeutics, Inc., Healthcare stocks news, Read more ...

Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilarginase Clinically Impactful Responses Captured by Mobility and Adaptive Behavior Assessments Management to Host Conference Call at 8:30 a.m. ET on Monday, April 8 AUSTIN, Texas, April 07, ...

AUSTIN, Texas, April 01, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that updated Phase 1/2 data...

AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that Anthony G. Quinn, M.B....

Aeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call March 7, 2019 04:30 pm ET Company Participants David Calusdian - IR, Sharon Merrill Associates Anthony Quinn - Chief Executive Officer Charles York - Chief Financial Officer Jim Wooldridge - Chief Medical Officer ...

Aeglea BioTherapeutics (NASDAQ: AGLE ): FY GAAP EPS of -$2.13 misses by $0.54 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...

On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with Pegzilarginase Cancer Indication-Phase 2 Combination Study Initiated Gross Proceeds of $69 Million from F...

AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced plans to host its fourth qua...